Rockefeller Capital Management
BLRX

Rockefeller Capital Management’s BioLineRX BLRX Stock Holding History

Rockefeller Capital Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28 Hold
12
– – ﹤0.01% 4657
2025
Q4 		$33 Hold
12
– – ﹤0.01% 4650
2025
Q3 		$45 Buy
+12
New +$48 ﹤0.01% 4398

Other funds holding BLRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Rockefeller Capital Management's BLRX Position: Q1 2026 in Review

Rockefeller Capital Management held its BioLineRX (BLRX) position steady in Q1 2026 at 12 shares worth $28. The position accounts for ﹤0.01% of the portfolio, ranked #4657.

Rockefeller Capital Management first reported a position in BLRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $45 in Q3 2025. 13 funds tracked by Wall St. Rank hold BLRX as of Q1 2026.

  • Rockefeller Capital Management held 12 shares of BioLineRX worth $28 as of Q1 2026.
  • Rockefeller Capital Management left its BioLineRX share count unchanged in Q1 2026.
  • BioLineRX made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4657 holding.
  • Rockefeller Capital Management first reported a position in BioLineRX in Q3 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's BioLineRX position peaked at $45 in Q3 2025.
  • 13 funds tracked by Wall St. Rank held BioLineRX as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.